Literature DB >> 30637565

Return to work after surgical treatment for malignant pleural mesothelioma: report of a case.

Masaru Takenaka1, Yoshinobu Ichiki2, Akihiro Taira2, Shinji Shinohara2, Taiji Kuwata2, Ayako Hirai2, Naoko Imanishi2, Kazue Yoneda2, Noriaki Tsubota3, Fumihiro Tanaka2.   

Abstract

We report the case of a 56-year-old woman who underwent pleural biopsy to identify the cause of the right pleural effusion. The pathological diagnosis was epithelial malignant pleural mesothelioma. The patient worked as a junior high school teacher and strongly hoped for continuing work. Thus, we performed pleurectomy/decortication (P/D) as a curative surgery. The operative findings showed pleural thickening that in the lower lobe of the lung. Thus, peeling of the lower lobe was performed. Pleural biopsy was only performed on the upper and middle lobes. As a result, the operation was limited P/D. The pathological findings showed a small number of mesothelioma cells in the upper and middle lobes. The patient received four courses of cisplatin plus pemetrexed systemic chemotherapy after surgery. Continuous maintenance chemotherapy using pemetrexed has been performed until the time of writing. At present, she has continued her work for 6 years after the operation and has extended her retirement age without recurrence.

Entities:  

Keywords:  Incomplete resection; Long-term survival; Maintenance chemotherapy; Malignant pleural mesothelioma; Pleurectomy/decortication

Mesh:

Year:  2019        PMID: 30637565     DOI: 10.1007/s11748-019-01064-z

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  10 in total

Review 1.  Extrapleural pneumonectomy is the preferred surgical management in the multimodality therapy of pleural mesothelioma: con argument.

Authors:  Robert B Cameron
Journal:  Ann Surg Oncol       Date:  2006-10-25       Impact factor: 5.344

Review 2.  Novel systemic therapy against malignant pleural mesothelioma.

Authors:  Michael R Mancuso; Joel W Neal
Journal:  Transl Lung Cancer Res       Date:  2017-06

3.  A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.

Authors:  Nobukazu Fujimoto; Keisuke Aoe; Toshiyuki Kozuki; Isao Oze; Katsuya Kato; Takumi Kishimoto; Katsuyuki Hotta
Journal:  Clin Lung Cancer       Date:  2018-05-09       Impact factor: 4.785

4.  Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.

Authors:  Takayuki Takeda; Hideki Itano; Shinichi Fukita; Masahiko Saitoh; Sorou Takeda
Journal:  Intern Med       Date:  2014-10-15       Impact factor: 1.271

5.  Non-incisional pleurectomy-decortication for malignant pleural mesothelioma.

Authors:  Fumihiro Tanaka; Naoko Imanishi; Masaru Takenaka; Akihiro Taira
Journal:  Surg Today       Date:  2018-02-28       Impact factor: 2.549

6.  Initial analysis of the international association for the study of lung cancer mesothelioma database.

Authors:  Valerie W Rusch; Dorothy Giroux; Catherine Kennedy; Enrico Ruffini; Ayten K Cangir; David Rice; Harvey Pass; Hisao Asamura; David Waller; John Edwards; Walter Weder; Hans Hoffmann; Jan P van Meerbeeck
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

7.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

8.  Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.

Authors:  Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto
Journal:  Lancet Oncol       Date:  2011-06-30       Impact factor: 41.316

Review 9.  Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.

Authors:  Xu-Quan Jing; Lei Zhou; Xin-Dong Sun; Jin-Ming Yu; Xue Meng
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 10.  New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.

Authors:  Marika Rossini; Paola Rizzo; Ilaria Bononi; Anthony Clementz; Roberto Ferrari; Fernanda Martini; Mauro G Tognon
Journal:  Front Oncol       Date:  2018-04-03       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.